Report : Biofilms Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Product (Debridement Equipment, Gauzes and Dressings, Grafts and Matrices, and Other Products), Wound Type (Traumatic and Surgical Wounds, Diabetic Foot Ulcers, Pressure Ulcers, Venous Leg Ulcers, and Other Wounds), and End User (Hospitals, Home Care Settings, and Other End Users)
Traumatic and Surgical Wounds Segment to Register Highest CAGR during 2020–2027
According to our latest study on “Biofilms Treatment Market Forecast to 2027 – COVID-19 Impact and Global Analysis – by Product, Wound Type, and End User,” the market was valued at US$ 1,590.31 million in 2019 and is projected to reach US$ 2,825.80 million by 2027; it is expected to grow at a CAGR of 7.5% during 2020–2027. The report highlights trends prevailing in the global biofilms treatment market, and the factors driving and restraining the market growth.
The global biofilms treatment market, based on wound type, is segmented into traumatic and surgical wounds, diabetic foot ulcers, pressure ulcers, venous leg ulcers, and other wounds. In 2019, the traumatic and surgical wounds segment accounted for the highest share of the market. The market growth for this segment is attributed to the increasing incidence of traumatic and surgical injuries, and rising awareness of benefits provided by wound care products.
The growth of the biofilms treatment market is driven by the increasing incidence of surgical, chronic, traumatic, and burn injuries. However, the high cost of treating wounds restrains the growth of the market. Mimedx Group Inc., Convatec Group Plc, Coloplast A/S, Mölnlycke Healthcare AB, Organogenesis Holdings Inc., Integra Lifesciences Holdings Corporation, B. Braun Melsungen AG, Paul Hartmann AG, Medline Industries Inc, and Smith and Nephew Plc. are among the companies operating in the market.
The report segments global biofilms treatment market as follows:
By Wound Type
By End User